ATE370934T1 - Substituierte dihydrophenanthridin-sulfonamide - Google Patents

Substituierte dihydrophenanthridin-sulfonamide

Info

Publication number
ATE370934T1
ATE370934T1 AT03796577T AT03796577T ATE370934T1 AT E370934 T1 ATE370934 T1 AT E370934T1 AT 03796577 T AT03796577 T AT 03796577T AT 03796577 T AT03796577 T AT 03796577T AT E370934 T1 ATE370934 T1 AT E370934T1
Authority
AT
Austria
Prior art keywords
dihydrophenanthridine
sulfonamides
substituted
arthritis
diseases
Prior art date
Application number
AT03796577T
Other languages
English (en)
Inventor
Albert Molinari
Mark Ashwell
Brian Ridgway
Amedeco Failli
William Moore
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32474616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE370934(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE370934T1 publication Critical patent/ATE370934T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • C07D221/12Phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03796577T 2002-12-04 2003-12-02 Substituierte dihydrophenanthridin-sulfonamide ATE370934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43094902P 2002-12-04 2002-12-04
US10/718,461 US6894061B2 (en) 2002-12-04 2003-11-20 Substituted dihydrophenanthridinesulfonamides

Publications (1)

Publication Number Publication Date
ATE370934T1 true ATE370934T1 (de) 2007-09-15

Family

ID=32474616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03796577T ATE370934T1 (de) 2002-12-04 2003-12-02 Substituierte dihydrophenanthridin-sulfonamide

Country Status (19)

Country Link
US (1) US6894061B2 (de)
EP (1) EP1567502B1 (de)
JP (1) JP4465280B2 (de)
KR (1) KR20050085321A (de)
AT (1) ATE370934T1 (de)
AU (1) AU2003298819A1 (de)
BR (1) BR0316196A (de)
CA (1) CA2508329A1 (de)
CR (1) CR7854A (de)
DE (1) DE60315874T2 (de)
DK (1) DK1567502T3 (de)
EC (1) ECSP055832A (de)
ES (1) ES2291739T3 (de)
MX (1) MXPA05006003A (de)
NO (1) NO20053204L (de)
NZ (1) NZ540440A (de)
RU (1) RU2005118070A (de)
TW (1) TW200510322A (de)
WO (1) WO2004050631A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113405A1 (en) * 2003-09-24 2005-05-26 Wyeth Methods of treating rheumatoid arthritis using NF-kB inhibitors
US20050119276A1 (en) * 2003-09-24 2005-06-02 Wyeth Methods of treating inflammatory bowel disease using NF-kB inhibitors
EP1652841A1 (de) * 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Neue Phenanthridinderivate als Inhibitoren der Hyperproliferation von T Zellen und/oder Keratinocyten
CN1968932A (zh) 2004-06-18 2007-05-23 惠氏公司 制备6-烷基-5-芳基磺酰基-二氢菲啶的方法
US7304073B2 (en) * 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
WO2006028875A1 (en) * 2004-09-02 2006-03-16 Wyeth Phenanthridine carbonyl phenols as cytokine modulators
US7555415B2 (en) 2005-01-19 2009-06-30 Wyeth Methods for the design of estrogen receptor ligands
HU230518B1 (hu) * 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
EP2520561B1 (de) 2007-06-08 2016-02-10 MannKind Corporation IRE-1a-Inhibitoren
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
JP2018515491A (ja) * 2015-05-05 2018-06-14 リセラ・コーポレイションLycera Corporation RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
US12084456B2 (en) 2018-12-05 2024-09-10 The Board Of Trustees Of The University Of Illinois Isocarbostyril alkaloids and functionalization thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135947A (en) 1965-04-20 1968-12-11 Aspro Nicholas Ltd Novel biologically active derivatives of phenanthridone
EP0509756A1 (de) 1991-04-16 1992-10-21 Merck & Co. Inc. 2-Phenanthridonyl-carbapeneme mit kationisierenden Substituenten
EP0509780A1 (de) 1991-04-16 1992-10-21 Merck & Co. Inc. 2-Phenanthridonyl-carbapeneme
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
US5726186A (en) 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
JP2001510827A (ja) 1997-07-25 2001-08-07 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換6−フェニルフェナントリジン
EP1650193A3 (de) 1999-01-15 2006-10-04 ALTANA Pharma AG 6-Phenylphenanthridine mit PDE-IV hemmender Wirkung
CA2360386A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
WO2002005616A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators

Also Published As

Publication number Publication date
NO20053204D0 (no) 2005-06-30
WO2004050631A1 (en) 2004-06-17
CR7854A (es) 2006-04-28
DK1567502T3 (da) 2007-10-29
BR0316196A (pt) 2005-09-27
US20040167155A1 (en) 2004-08-26
CA2508329A1 (en) 2004-06-17
JP4465280B2 (ja) 2010-05-19
EP1567502A1 (de) 2005-08-31
DE60315874D1 (de) 2007-10-04
JP2006510631A (ja) 2006-03-30
EP1567502B1 (de) 2007-08-22
AU2003298819A1 (en) 2004-06-23
ECSP055832A (es) 2005-08-11
TW200510322A (en) 2005-03-16
KR20050085321A (ko) 2005-08-29
RU2005118070A (ru) 2006-01-27
ES2291739T3 (es) 2008-03-01
MXPA05006003A (es) 2005-08-18
NO20053204L (no) 2005-09-05
DE60315874T2 (de) 2008-05-15
US6894061B2 (en) 2005-05-17
NZ540440A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
DE60315874D1 (de) Substituierte dihydrophenanthridin-sulfonamide
MXPA05011581A (es) Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos.
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
MX2010003612A (es) Derivados de oxadiazol.
CY1111363T1 (el) Τρικυκλικος ανταγωνιστης υποδοχεων θρομβινης
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
ITMI20030709A1 (it) Miscele di stabilizzanti.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200501274A1 (ru) Пиразолы и способы их получения и применения
DK1507775T3 (da) Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EA200300933A1 (ru) Новое применение соединения из класса пептидов для лечения аллодинии или других различных типов хронической или фантомной боли
UY26851A1 (es) Derivados de la 4-fenilpiridina
NO20070089L (no) DPP-IV inhibitorer
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
EA200400438A1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии
DE60124717D1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
PT1334094E (pt) Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol
BRPI0415355A (pt) triarilimidazóis
WO2004056762A3 (en) Novel aminobenzophenone compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties